So, as a loyal alum of a lab studying tumor vasculature, I'm contractually obligated to tell you that, alas, once you have built a biomolecule that sticks prefe

So, as a loyal alum of a lab studying tumor vasculature, I'm contractually obligated to tell you that, alas, once you have built a biomolecule that sticks preferentially to cancer cells you must still deliver that molecule to the cells. And that is hard. It is hard because tumors have lousy blood vessel networks. Normal cells have nicely designed blood vessels an optimum distance away. Tumors do not. I'm not surprised that this study was for stomach cancer biopsy alternatives. Presumably it's relatively easy to deliver antibodies to cells that are sitting there on the lining of the stomach. And this much is a big win, no question - nobody who has actually had an invasive gastric procedure would fail to applaud the invention of a better alternative. But other cancers may be harder. Plenty of work left to do.